SENATE BILL REPORT
This analysis was prepared by non-partisan legislative staff for the use of legislative members in their deliberations. This analysis is not a part of the legislation nor does it constitute a statement of legislative intent.
As Reported by Senate Committee On:
Health Care, January 25, 2016
Title: An act relating to the prescribing of schedule II controlled substances.
Brief Description: Allowing the prescription of schedule II controlled substances to treat certain disease states and conditions.
Sponsors: Senators Rivers, Keiser, Cleveland, Miloscia and Chase.
Committee Activity: Health Care: 1/19/16, 1/25/16 [DPS].
SENATE COMMITTEE ON HEALTH CARE
Majority Report: That Substitute Senate Bill No. 6238 be substituted therefor, and the substitute bill do pass.
Signed by Senators Becker, Chair; Dammeier, Vice Chair; Cleveland, Ranking Minority Member; Angel, Bailey, Baumgartner, Brown, Conway, Frockt, Jayapal, Keiser, Parlette and Rivers.
Staff: Kathleen Buchli (786-7488)
Background: The Controlled Substances Act prohibits practitioners from prescribing amphetamines or Schedule II non-narcotic stimulants except for the treatment of specific disease states or conditions as set forth in statute and rule. Currently, Schedule II non-narcotic stimulants are permitted to be prescribed for the treatment of narcolepsy, depression, multiple sclerosis, and other listed medical conditions.
On January 30, 2015, the United States Food and Drug Administration (FDA) approved lisdexamfetamine dimesylate, a Schedule II non-narcotic stimulant, to treat binge-eating disorder in adults. Binge-eating disorder is not one of the medical conditions in statute for which Schedule II non-narcotic stimulants may be prescribed.
Summary of Bill (Recommended Substitute): Binge-eating disorder is added to the medical conditions for which Schedule II non-narcotic stimulants may be prescribed.
EFFECT OF CHANGES MADE BY HEALTH CARE COMMITTEE (Recommended Substitute): Removes the provision expanding uses of Schedule II controlled substances to drugs approved for such use by the Food and Drug Administration.
Fiscal Note: Not requested.
Committee/Commission/Task Force Created: No.
Effective Date: Ninety days after adjournment of session in which bill is passed.
Staff Summary of Public Testimony on Original Bill: PRO: Vyvanse has been approved for the treatment of binge eating disorder by the FDA. This will solve issues relating to FDA approval of a drug for a use that is not in statute. It will increase access to treatment and care. It is important for the treatment of a condition that impacts many young men and women.
Persons Testifying on Original Bill: PRO: Senator Rivers, Jeff Gombosky, Shire U.S. Inc.; BJ Canvor, One in Four Chronic Health.
Persons Signed In To Testify But Not Testifying on Original Bill: No one.